Sentence examples for median methylation difference from inspiring English sources

bEffect size is calculated as the median methylation difference between smokers and non-smokers.

At this site, an 8.1%9595% CI 6.9, 9.3%) reduction in cord blood methylation with sustained prenatal smoking exposure was identified, which is in line with the median methylation difference of medium and high cotinine versus no exposure in a previous EWAS (18), which was 5.4 and 9.9%, respectively.

At 12 loci, the effect size (calculated as median % methylation difference) was greater than 5% (Table  2, summary and test statistics for all CpG sites in Additional file 1).

Furthermore, the magnitude of the difference in median methylation between PM and MN cell types was much smaller than the difference in median methylation between smokers and nonsmokers in both the MoBa and NEST study populations.

Furthermore, the distribution of methylation showed the largest difference in median methylation between the two groups of patients.

For the percent difference in median methylation by cell type, the maximum was 3.1% and the mean was 1.0%.

For our top CpG AHRR cg05575921, the percent difference in median methylation was 0.31% by cell type compared with 7.52% for smokers compared with nonsmokers in MoBa (7.67% in NEST).

In contrast, for the percent difference in median methylation between smokers and non-smokers measured in whole blood, which is a mixture of these two major cell types (PM and MN), the maximum was 13.7% (MoBa) and 15.1% (NEST), and the mean was 5.3% (MoBa) and 5.0% (NEST).

In Table 3, the percent differences in median methylation (smokers – nonsmokers) were incorrect for two CpGs; the correct values are –1.2 (MoBa) and –1.1 (NEST) for TTC7B cg18655025, and –1.8 (MoBa) and –0.3 (NEST) for HLA-DPB2 cg11715943.

Median methylation intensities at the nine CpGs were determined for strata of sociodemographic characteristics, lifestyle factors, and prevalent diseases; differences in methylation intensities between strata were examined by Kruskal Wallis tests.

Kaplan Meier survival curves were generated to visualise differences in survival and recurrence between high and low LINE-1 methylation groups, based on median methylation percentage (57.4%) of stage I and II patients in the validation study.